---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013654"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:22:03.378640+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Glucotrack reports FY2025 net loss $19.4M; cash $7.4M; plans IDE filing Q2 2026

## Summary
- Net loss for FY2025 was $19.4M, down from $22.6M in 2024; no product revenue.
- Cash and equivalents $7.4M at Dec 31, 2025, up from $5.6M; raised $4.0M private placement in Dec 2025.
- R&D expenses $9.8M vs $9.5M; G&A $6.3M vs $5.1M year-over-year.
- Expects to file IDE with FDA in Q2 2026 to start US clinical feasibility study of implantable CBGM in H2 2026.
- Believes existing cash sufficient only through Spring 2026 to fund IDE submission and trial initiation.

## SEC filing metadata
- accession: 0001493152-26-013654
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315226013654/0001493152-26-013654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315226013654/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013654
- JSON: https://secwatch.observer/filing/0001493152-26-013654.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013654.txt

## Key facts
- Earnings Releases
  Glucotrack, Inc. reported full year ended December 31, 2025 results: net income Net loss for the full year 2025 was $19.4 million.
  - Period: full year ended December 31, 2025
  - Net income: Net loss for the full year 2025 was $19.4 million
  - Result: reported results
  source text: Glucotrack, Inc. (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506983/000149315226013654/0001493152-26-013654-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.